Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4457346 | 0.85 | MAPT (0.50) | ALDH1A1TSHRCYP3A4MAPTMEN1 | |
| SCHEMBL28072926 | 0.79 | TSHR (0.50) | ALDH1A1TSHRCYP3A4RECQLHSD17B10 | |
| SCHEMBL6733075 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TSHRCYP3A4MAPTMEN1 | |
| SCHEMBL31093806 | 0.79 | TSHR (0.50) | ALDH1A1TSHRCYP3A4RECQLHSD17B10 | |
| SCHEMBL1473281 | 0.76 | TDP1 (0.56) | ALDH1A1TSHRCYP3A4HSD17B10SMN1; SMN2 | |
| SCHEMBL14494900 | 0.76 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP3A4RECQLHSD17B10 | |
| SCHEMBL30702012 | 0.76 | ALDH1A1 (0.42) | ALDH1A1TSHRCYP3A4RECQLHSD17B10 | |
| SCHEMBL16026726 | 0.76 | TSHR (0.44) | ALDH1A1TSHRCYP3A4RECQLHSD17B10 | |
| SCHEMBL8159027 | 0.76 | GPR35 (0.52) | ALDH1A1TSHRRECQLHSD17B10MAPT | |
| SCHEMBL13482304 | 0.76 | MAPT (0.40) | ALDH1A1CYP3A4MAPTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-112996496-A | substituted-3H-imidazo [4,5-c ] pyridines and 1H-pyrrolo [2,3-c ] pyridines as novel ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) and interferon gene Stimulator (STING) modulators for cancer immunotherapy | 斯汀格瑞治疗股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020119606-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-06-18 | — | — | WO | disclosed |
| US-20170349584-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2017-12-07 | — | — | US | disclosed |
| US-20170216299-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2017-08-03 | — | — | US | disclosed |
| CN-103435561-B | A kind of Novel D-amino acid oxidase inhibitor and preparation thereof and application | 上海交通大学 | 2016-08-10 | — | — | CN | disclosed |
| CN-101538267-B | Imidazo [4,5-c ] pyridine compounds and methods of antiviral treatment | LEUVEN K U RES & DEV | 2015-04-29 | — | — | CN | disclosed |
| CN-103435561-A | Novel D-amino acid oxidase inhibitor and preparation and application thereof | UNIV SHANGHAI JIAOTONG | 2013-12-11 | — | — | CN | disclosed |
| EP-1706403-B1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | LEUVEN K U RES & DEV (BE) | 2012-02-08 | — | — | EP | disclosed |
| EP-2161273-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U.Leuven Research & Development (BE) | 2010-03-10 | — | — | EP | disclosed |
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-02-04 | — | — | US | disclosed |
| US-7648998-B2 | 5-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine; hepatitis-C-virus | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2010-01-19 | — | — | US | disclosed |
| CN-101538267-A | Imidazo [4, 5-c ] pyridine compounds and methods of antiviral treatment | LEUVEN K U RES & DEV GILEAD SC (BE) | 2009-09-23 | — | — | CN | disclosed |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2007-10-18 | — | — | US | disclosed |
| CN-1902198-A | Imidazo [4, 5-c ] pyridine compounds and methods of antiviral treatment | K U LEUVEN RES & DEV GERHARD P (BE) | 2007-01-24 | — | — | CN | disclosed |
| EP-1706403-A2 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U.Leuven Research & Development (BE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | K.U. LEUVEN RESEARCH & DEVELOPMENT, GERHARD PUERSTINGER AND GILEAD SCIENCES, INC. | 2005-10-06 | — | — | US | disclosed |
| WO-2005063744-A2 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028301-A1 | IMIDAZO[4,5-c]PYRIDINE COMPOUNDS AND METHODS OF ANTIVIRAL TREATMENT | CYP3A5, TPMT, ZC3HAV1 | ALDH1A1 490/4885TSHR 3313/4885CYP3A4 10/4885 |
| US-20070244148-A1 | Imidazo 4,5-C Pyridine Compounds and Methods of Antiviral Treatment | ZC3HAV1, TPMT, DPP4 | ALDH1A1 1580/4885TSHR 3704/4885CYP3A4 13/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ALDH1A1 128/4885TSHR 728/4885CYP3A4 63/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | ALDH1A1 128/4885TSHR 728/4885CYP3A4 63/4885 |
| US-20050222198-A1 | Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment | CYP3A5, TPMT, TYMP | ALDH1A1 451/4885TSHR 3222/4885CYP3A4 10/4885 |
| US-20170216299-A1 | 3-(3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | ALDH1A1 1312/4885TSHR 4204/4885CYP3A4 1908/4885 |
| US-20170349584-A1 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | WNT3A, WNT1, WNT3 | ALDH1A1 1762/4885TSHR 4652/4885CYP3A4 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.